Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Secukinumab
Cosentyx
Routinely available
NICE (TA445 (SMC 1167/16))
16/11/2016

Indication

Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Routinely available in line with national guidance

Formulation

150mg solution for injection in pre-filled pen and pre-filled syringe

Comments

November 2016 - Included on the LJF as first choice, Specialist Use only, for the indication in question. May 2017 - NICE MTA advice: SMC advice 1167/16 is superseded by NICE TA445. July 2019 (as per LJF) - Routinely available in line with national guidance. Included on the Additional List, for Specialist Use only.

Link to Advice

TA445 (SMC 1167/16)

Advice Published

24/05/2017